Analytical Data
-
Gene name
E1A
- Application
-
Alternative Names
Early E1A 32 kDa protein
-
Species
Pan-species (General)
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P03255
-
Expression Region
Met1~Tyr184
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
E1A proteins, derived from adenoviruses, have garnered significant attention in molecular biology and cancer research due to their unique ability to modulate cellular processes. Initially discovered for their role in viral replication, E1A proteins function as transcriptional regulators by interacting with various cellular proteins, including tumor suppressors like pRb (retinoblastoma protein) and p300/CBP (CREB-binding protein). This interaction disrupts normal cell cycle regulation and promotes cell proliferation, making E1A a potent oncogene. Researchers have leveraged E1A's properties to explore its potential in gene therapies and cancer treatments, aiming to harness its ability to induce apoptosis in cancer cells while sparing normal cells. Furthermore, E1A's mechanism of action provides valuable insights into the molecular pathways governing cell growth and differentiation, contributing to a better understanding of tumorigenesis. As a result, ongoing studies focus on the therapeutic applications of E1A, including its use in oncolytic virotherapy, where modified adenoviruses carrying the E1A gene are designed to selectively target and kill malignant cells, thus offering a promising strategy for cancer treatment.
